Keytruda Approved for Previously Treated PD-L1–Positive Cervical Cancer

The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have recurrent or metastatic cervical cancer that progresses on or after chemotherapy and whose tumors express programmed death ligand-1 (PD-L1).